PAVmed Inc. (PAVM) Stock Score, Valuation & Financial Research
PAVmed Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 17/100.
Quick answer for PAVM
PAVmed Inc. currently has a Wall Street Score of 17/100. The stored market price is $4.18. Its financial score is 0/100. Its valuation score is 0/100. The latest WSS change is -2.7 points. These figures are a research snapshot, not a buy or sell recommendation.
What PAVmed Inc. does
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations includ
PAVM financial snapshot
- Wall Street Score:
- 17/100
- Current price:
- $4.18
- Market capitalization:
- $26.7M
- Revenue:
- $112K
- Net income:
- $-12.1M
- Free cash flow:
- $-5.21B
- Cash:
- $3.8M
- Total debt:
- $17.1M
- EPS:
- -16.36
- Financial score:
- 0/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is +0.6%.
- Free cash flow is $-5.21B, showing cash burn in the current stored period.
- The balance sheet shows $3.8M of cash versus $17.1M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -2.7 points: PAVM decreased 2.7 points because Asset declined by 12.6 points, Capital declined by 23 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 0/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research PAVM
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.